1. Home
  2. VMET vs ABCL Comparison

VMET vs ABCL Comparison

Compare VMET & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VMET

Versamet Royalties Corporation Common Stock

N/A

Current Price

$12.08

Market Cap

1.3B

Sector

N/A

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.63

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMET
ABCL
Founded
2011
2012
Country
Canada
Canada
Employees
8
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VMET
ABCL
Price
$12.08
$5.63
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.40
AVG Volume (30 Days)
157.7K
8.4M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
$185.47
N/A
Revenue Next Year
$16.05
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
160.56
52 Week Low
$9.10
$2.45
52 Week High
$13.81
$6.79

Technical Indicators

Market Signals
Indicator
VMET
ABCL
Relative Strength Index (RSI) 49.35 55.07
Support Level $10.85 $5.34
Resistance Level $13.62 $5.63
Average True Range (ATR) 0.79 0.56
MACD 0.01 0.05
Stochastic Oscillator 50.14 56.84

Price Performance

Historical Comparison
VMET
ABCL

About VMET Versamet Royalties Corporation Common Stock

Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: